Form 4: Ionis Pharmaceuticals Executive Sells Shares

Ionis Pharmaceuticals EVP and General Counsel Patrick R. O'Neil sold 3,069 shares of common stock on June 26, 2026, valued at approximately $80 per share, as part of a pre-arranged trading plan.

Summary

• Patrick R. O'Neil, EVP, CLO & General Counsel at Ionis Pharmaceuticals Inc. (IONS), reported a transaction on June 26, 2026.
• He sold 3,069 shares of common stock.
• The sale was executed at a price of $80 per share.
• This transaction was made under a Rule 10b5-1 Trading Plan adopted on December 8, 2025.
• Following the transaction, O'Neil beneficially owns 61,470 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The sale was conducted under a pre-arranged trading plan, indicating it's likely part of personal financial management rather than a reflection of negative company outlook.

Negatives

• An executive sold a portion of their holdings in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction by an executive.

Industry Context

StockSavvy.ai notes that insider stock sales, particularly when conducted under a Rule 10b5-1 plan, are common and often reflect an executive's personal financial planning rather than a negative outlook on the company's prospects. However, significant sales can sometimes be interpreted by the market as a signal, depending on the volume and the executive's role.

Stakeholder Impact

• Shareholders: May observe the sale as a minor event, especially given it was part of a pre-arranged plan. The impact on share price is likely minimal unless it's part of a larger trend of insider selling.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Patrick R. O'Neil, Executive Compensation